Attached files
file | filename |
---|---|
EX-10.1 - EX-10.1 - Echo Therapeutics, Inc. | w77325exv10w1.htm |
EX-4.1 - EX-4.1 - Echo Therapeutics, Inc. | w77325exv4w1.htm |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 4, 2010
Echo Therapeutics, Inc.
(Exact name of Company as specified in its charter)
Delaware (State or other jurisdiction of Incorporation) |
000-23017 (Commission File Number) |
41-1649949 (I.R.S. Employer Identification No.) |
10 Forge Parkway Franklin, Massachusetts (Address of principal executive offices) |
02038 (Zip Code) |
Companys telephone number, including area code: (508) 553-8850
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Company under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Table of Contents
Item 1.01. Entry into a Material Definitive Agreement.
On February 4, 2010 Echo Therapeutics, Inc. (the Company) entered into a Common Stock and
Warrant Purchase Agreement (the Purchase Agreement) with certain strategic institutional and
accredited investors (the Investors) in connection with the Companys private placement (the
Financing) of shares of its Common Stock, $0.01 par value (the Common Stock), at a price of
$1.50 per share (the Shares). Under the terms of the Purchase Agreement, each Investor shall
receive warrants to purchase a number of shares of Common Stock with an exercise price of $2.25 per
share equal to fifty percent (50%) of the number of Shares purchased by such Investor (the
Warrants).
The Company received proceeds of approximately $2,036,000 in connection with the Financing.
The Company intends to use the net proceeds of the Financing primarily for working capital and
general corporate purposes.
Pursuant to the Purchase Agreement, the Company issued an aggregate of 678,657 Warrants to the
Investors. The Warrants are immediately exercisable and expire no later than February 9, 2015. The
exercise price is subject to adjustment for stock splits, combinations or similar events. The
Warrants allow for cashless exercise. An exercise under the Warrants may not result in the holder
beneficially owning more than 4.99% or 9.99%, as applicable, of all of the Common Stock outstanding
at the time; provided, however, that a holder may waive the foregoing provision upon sixty-one (61)
days advance written notice to the Company.
The offer, sale and issuance to the investors of the Shares, Warrants, and shares of Common
Stock issuable upon the exercise of the Warrants have been made in reliance on the statutory
exemption from registration in Section 4(2) of the Securities Act of 1933, as amended (the
Securities Act), have not been and will not be registered under the Securities Act, and unless so
registered, may not be offered or sold in the United States, except pursuant to an applicable
exemption from the registration requirements of the Securities Act, and applicable state securities
laws. The Company is not required to register for resale under the Securities Act (i) the Shares
issued to the Investors, (ii) the Warrants or (iii) the Common Stock issuable upon the exercise of
the Warrants.
In connection with the Financing, the Company retained Boenning & Scattergood, Inc. and
Burnham Hill Partners LLC as its placement agents (each, a Placement Agent). The Company agreed
to pay each Placement Agent for its services as follows: (a) a cash fee equal to seven percent (7%)
of the gross cash proceeds received by the Company in connection with the Financing from Investors
the Placement Agent directly introduced to the Financing; and (b) warrants to acquire a number of
shares of Common Stock of the Company equal to 10% of the number of Shares issued to the Investors
directly introduced to the Financing by the Placement Agent at a per share exercise price equal to
the exercise price of the Warrants and with such other terms and conditions as are equal or
substantially similar to those included in the Warrants. The Company also agreed to pay reasonable
out of pocket expenses of each Placement Agent incurred in connection with the Financing in an
amount not to exceed $5,000 per Placement Agent.
The foregoing descriptions of the Purchase Agreement, the Warrants and the transactions
contemplated therein and thereby do not purport to be complete and are qualified in their entirety
by reference to the full text of such agreements and instruments, which are filed as exhibits
hereto and are incorporated herein by reference.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
Sheet Arrangement of a Company.
The information set forth in Item 1.01 is incorporated by reference into this Item 2.03.
Table of Contents
Item 3.02 Unregistered Sales of Equity Securities.
The information set forth under Item 1.01 is incorporated by reference into this Item 3.02.
The Companys issuance of the Shares pursuant to the Purchase Agreement was made in a transaction
not involving any public offering pursuant to an exemption from registration under Section 4(2) of
the Securities Act. The Shares may not be offered or sold in the United States in the absence of an
effective registration statement or an exemption from the registration requirements under the
Securities Act. An appropriate restricted securities legend was placed on the Shares issued
pursuant to the Purchase Agreement.
Item 9.01 Financial Statements and Exhibits.
The Exhibits listed in the Exhibit Index immediately preceding such Exhibits are filed with or
incorporated by reference in this report.
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 10, 2010 |
ECHO THERAPEUTICS, INC. |
|||
By: | /s/ Harry G. Mitchell | |||
Harry G. Mitchell | ||||
Chief Operating Officer, Chief Financial Officer and Treasurer |
||||
Table of Contents
EXHIBIT INDEX
Exhibit No. | Description | |
4.1
|
Form of Warrant to Purchase Common Stock | |
10.1
|
Common Stock and Warrant Purchase Agreement by and among the Company and the Investors named therein, dated as of February 4, 2010 * |
* | Schedules and attachments have been omitted but will be provided to the Commission upon request. |